reports
Eisai Initiates Rolling Biologics License Application to US FDA for LE...
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administra...
Hudson Acquisition I Corp. and Aiways Automobile Europe GmbH Enter int...
Hudson Acquisition I Corp. and Aiways Automobile Europe GmbH Enter into Letter Agreement for Business Combination New York, NY, May 14, 2024 (GLOBE NEWSWIRE) -- Hudson Acquisition I Corp. (NASDAQ: “HUDA”) today announced it has signed a letter agreement with Aiways Automobile Europe GmbH (“Aiways Europe”) for a business combination (the “de-SPAC”). The shareholders of Aiways Europe will receive newly issued shares of HUDA common stock in an aggregate amount representing an equity valuation of approximately US$400 million. The de-SPAC is expected to close on or around December 3...
Imperial Announces Normal Course Issuer Bid
Imperial Announces Normal Course Issuer Bid VANCOUVER, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) -- Imperial Metals Corporation (“Imperial” or the “Company”) (TSX:III) announces the Toronto Stock Exchange (the “TSX”) has accepted the Company’s Notice of Intention to make a Normal Course Issuer Bid (the “Bid”) to be transacted through the facilities of the TSX or alternative Canadian trading systems. Pursuant to the Bid, the Company may purchase up to 809,357 common shares, which represents 0.5% of the total 161,871,341 common shares of the Company issued and outstanding as of May...
Moody's Ratings affirms Indiana University Foundation's (IN) Aaa; outl...
Moody's Ratings (Moody's) has affirmed Indiana University Foundation's (IUF) Aaa revenue bond rating. Total debt outstanding is approximately $150 million as of fiscal year end 2023. The outlook is stable. RATINGS RATIONALE The affirmation of Indiana University Foundation's Aaa revenue bond rati...
Moody's Ratings assigns Aa2 to District of Columbia Housing Finance Ag...
Moody's Ratings (Moody's) has assigned a rating of Aa2 to $47.945 million District of Columbia Housing Finance Agency's Multi-Family Development Program Bonds, Series 2024 A-1 and Series 2024 A-2 (collectively, the "Bonds"). Moody's currently maintains a rating of Aa2 with a stable outlook on the Mu...
PowerCo SE and NOVONIX Enter into a Testing and Development Agreement
PowerCo SE and NOVONIX Enter into a Testing and Development Agreement BRISBANE, Australia, May 15, 2024 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ: NVX, ASX: NVX), a leading battery materials and technology company, and PowerCo SE (“PowerCo”), a Volkswagen Group-owned battery cell company, have announced the signing of a non-exclusive Testing and Development Agreement (“TDA”). The work to be conducted under the TDA will include NOVONIX developing, testing, and analyzing synthetic graphite anode materials tailored to meet PowerCo’s requirements and upon successful completion of certain de...
Moody's Ratings downgrades Cabell Huntington Hospital, Inc. (WV) to Ba...
Moody's Ratings (Moody's) has downgraded Cabell Huntington Hospital, Inc.'s (WV) long term bond rating to Baa3 from Baa2. The outlook remains negative at the lower rating level. Cabell has approximately $340 million of outstanding debt. The downgrade to Baa3 is driven by Cabell's rapid decline of ...
ONWARD® Medical Schedules Webcast to Provide Q1 2024 Business Update
ONWARD® Medical Schedules Webcast to Provide Q1 2024 Business Update EINDHOVEN, the Netherlands, May 15, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces that it will host a webcast to discuss its Q1 2024 business highlights. The webcast will be held on May 23, 2024, at 2:30PM CET / 08:30AM ET. It will be hosted by CEO Dave Marver who will discuss highlights from Q1 2024 and provide ...
Calian Reports Record Results for the Second Quarter
Calian Reports Record Results for the Second Quarter (All amounts in release are in Canadian dollars) OTTAWA, May 14, 2024 (GLOBE NEWSWIRE) -- Calian® Group Ltd. (TSX:CGY), a diverse products and services company providing innovative healthcare, communications, learning and cybersecurity solutions, today released its results for the second quarter ended March 31, 2024. Q2-24 Highlights: Revenue up 19% to $201 millionGross margin at 34.8%, up from 30.9% last yearAdjusted EBITDA1 up over 50% to $25.7 millionOperating free cash flow1 of $17.8 millionNet liquidity of $157 millionAppointed ...
Calian annonce des résultats record au deuxième trimestre
Calian annonce des résultats record au deuxième trimestre (Tous les montants dans le communiqué sont en dollars canadiens.) OTTAWA, 14 mai 2024 (GLOBE NEWSWIRE) -- CalianMD Group Ltd. (TSX : CGY), une société de produits et services divers qui fournit des solutions novatrices dans les domaines des soins de santé, des communications, de l’apprentissage et de la cybersécurité, a publié aujourd’hui ses résultats pour le deuxième trimestre qui s’est terminé le 31 mars 2024. Faits saillants du deuxième trimestre de l’exercice 2024 : Revenus en hausse de 19 %, à 201 million...
- Jesper Ingildsen
Ambu (Buy, TP: DKK138.00) - Guidance still looks conservative
Having pre-released Q2 headline numbers and increased the 2024 guidance in mid-April, today’s detailed results provided few surprises. However, the important Endoscopy sales were slightly better than expected, and we find today’s guidance for >15% organic growth YOY (previously c15%) for that part of company still conservative, with potential for a further rise with the Q3 results. We reiterate our BUY and have increased our target price to DKK138 (130).
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.